Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail SkepticismETF Trends · Oct 12, 2026
AbbVie Completes Acquisition of Apogee TherapeuticsPRNewsWire · Sep 3, 2026
Deutsche Bank AG Acquires New Stake in Apogee Therapeutics Inc. $APGEDefense World · Aug 23, 2026
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayBenzinga · Aug 12, 2026
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline UpdatesGlobeNewsWire · Aug 10, 2026
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells $737,935.00 in StockDefense World · Aug 10, 2026Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$1.07 | -$1.14 | Miss |
| May 11, 2026 | -$1.07 | -$1.06 | Beat |
| Mar 2, 2026 | -$1.05 | -$1.03 | Beat |
| Nov 10, 2025 | -$1.12 | -$1.11 | Beat |
| Aug 11, 2025 | -$1.03 | -$1.13 | Miss |
| May 12, 2025 | -$1.19 | -$0.95 | Beat |